Corporations lock up your genome, while VCs flee biotech
Two posts worth checking out at VentureBeat Life Sciences:
1. Whiz-bang gene technology will soon let you play around with your own genome — but companies like 23andMe and Navigenics may lock it up and repeatedly charge you for access to it. Read about the emerging world of “corporate genomics” here.
2. Funding for biotech and medical-device startups seemed pretty stable in the third quarter, but a closer look revealed that VCs are dropping the sector like a hot potato.
Next Story: GE, Chevron investing big-time in clean technology
Previous Story: Google allies with Nielsen, edging further into $54 billion TV market
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.
VB Writers
Ben PopperEast Coast Editor
Dean TakahashiLead Writer, GamesBeat
Devindra HardawarNational Editor, MobileBeat Lead
Dylan TweneyExecutive Editor
ShoeEditor-in-Chief, GamesBeat
Heather KellySenior Editor
Jennifer Van GroveWriter
Jolie O'DellWriter
Matt MarshallFounder & Editor-in-Chief
Meghan KellyWriter
Sarah MitroffEditorial Assistant
Sean LudwigWriter
Sebastian HaleyReviews Editor, GamesBeat
Tom CheredarWriter
Ciara ByrneContributor
Julia PlevinContributor
Lindsey ComptonContributor
